Calculation of prevalence estimates through differential equations: Application to stroke-related disability

Neuroepidemiology

Volumn 31, Issue 1, 2008, Pages 57-66

  Mar, Javier ^a,c   Sainz Ezkerra, María ^a   Moler Cuiral, Jose Antonio ^b  

^a Hospital Alto Deba   (Spain)

^b PUBLIC UNIVERSITY OF NAVARRE   (Spain)

^c Hospital 'Alto Deba'   (Spain)

Author keywords

Differential equations; Disability prevalence; Stroke

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DISABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NEUROLOGIC DISEASE; PREVALENCE; PROBABILITY; STROKE; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISABLED PERSONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, THEORETICAL; PREVALENCE; RETROSPECTIVE STUDIES; STROKE;

EID: 46849111018     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140096     Document Type: Article

References (33)

1. World Health Organization: Neurological Disorders: Public Health Challenges. Geneva, WHO Press, 2006.
2. Rothman KJ, Greenland S: Measures of disease frequency; in Rothman KJ, Greenland S (eds): Modern Epidemiology. Philadelphia, Lippincott, Williams and Wilkins, 1998, pp 29-46.
3. Murray CJL, Lopez AD: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Harvard University Press, 1996.
4. Kalache A, Aboderin I: Stroke: the global burden. Health Policy Plan 1995;10:1-21.
5. Knapp M, Prince M: Dementia UK: The Full Report. London, Alzheimer's Society, 2007.
6. Weinstein M, O'Brien B, Hornberger J, Jackson J, Johannesson M, MCCabe C, Luce B: Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17.
7. Tom E, Schulman KE: Mathematical models in decision analysis. Infect Control Hosp Epidemiol 1994;18:65-73.
8. Sonnenberg FA, Beck R: Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
9. Brennan A, Akehurst R: Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 2000;17:445-459.
10. Caro JJ: Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-332.
11. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR: Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes. UKPDS 72 United Kingdom Prospective Diabetes Study (UKPDS 72). Diabetologia 2005;48:868-877.
12. Schlessinger L, Eddy DM: Archimedes: a new model for simulating health care systems. The mathematical formulation. J Biomed Inform 2002;35:37-50.
13. Boutayeb A, Twizell EH, Achouayb K, Chetouani A: A mathematical model for the burden of diabetes and its complications. Biomed Eng Online 2004;3:20.
14. Nokes DJ, Anderson RM: The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes. Epidemiol Infect 1988;101:1-20.
15. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ: A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 2003;1:4.
16. Murray CJ, Lopez AD: Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442.
17. Buti M, San Miguel R, Brosa M, Cabases JM, Medina M, Angel Casado MA, Fosbrook L, Esteban R: Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-645.
18. Hankey GJ: Stroke Treatment and Prevention: An Evidence-Based Approach. New York, Cambridge University Press, 2005.
19. Adams HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA, et al: Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1994;90:1588-1601.
20. American Heart Association: Heart Disease and Stroke Statistics - 2004 Update. Dallas, American Heart Association, 2003.
21. Arrazola A, Begiristain JM, Mar J: Atención hospitalaria a la enfermedad cerebrovascular aguda y situación de los pacientes a los 12 meses. Rev Neurol 2005;40:1781-1787.
22. Mar J, Begiristain JM, Arrazola A: Cost-Effectiveness Analysis of Thrombolytic Treatment for Stroke. Cerebrovasc Dis 2005;20:193-200.
23. Mahoney FJ, Barthel DW: Functional evaluation: the Barthel index. Md Med J 1965;14:61-65.
24. Ahrens W, Pigeot I: Handbook of Epidemiology. Berlin, Springer, 2005.
25. Mathews JH, Fink KD: Métodos Numéricos con Matlab. Madrid, Prentice Hall, 2000.
26. Freeman J, Hutchison GB: Prevalence, incidence and duration. Am J Epidemiol 1980;112:707-723.
27. Mar J, Sainz-Ezkerra M, Miranda-Serrano E: Calculation of prevalence through Markov models. Application to prevalence-based economic evaluation of thrombolysis for stroke. Med Decis Making 2008, Epub ahead of print.
28. Bonita R, Solomon N, Broad JB: Prevalence of stroke and stroke-related disability: estimates from the Auckland Stroke Studies. Stroke 1997;28:1898-1902.
29. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, et al: Global prevalence of dementia: a Delphi consensus. Lancet 2005;366:2112-2117.
30. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T: Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781-1787.
31. Kruijshaar ME, Barendregt JJ, van de Poll-Franse LV: Estimating the prevalence of breast cancer using a disease model: data problems and trends. Popul Health Metr 2003;1:5.
32. Nutt PC: Planning Methods for Health and Related Organizations. New York, John Wiley & Sons, 1984.
33. Rothwell PM: The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001;357:1612-1616.